A huge international study of a COVID-19 vaccine that aims to work with just one dose is underway as Johnson & Johnson begins dosing up to 60,000 volunteers, Associated Press has reported.
Hopes are high that answers about at least one of several candidates being tested in the U.S. could come
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
